NIPPON-SHOKUBAI
20.9.2022 15:31:37 CEST | Business Wire | Press release
NIPPON SHOKUBAI CO., LTD. (Headquarters: Osaka, Japan, President: Kazuhiro Noda, hereinafter “Nippon Shokubai”) (TOKYO:4114) aims to expand our LiFSI* business in China, the biggest market of lithium-ion batteries (hereinafter “LIB”). We hereby announce that, as part of this business expansion, we have reached agreement on investment in Hunan Fluopont New Materials Co., Ltd. (hereinafter “Hunan Fluopont”), a subsidiary of Shenzhen CAPCHEM Technology Co. Ltd. (hereinafter “Capchem”), who is currently making efforts to establish production facilities to enter LiFSI business.
*Lithium bis (fluorosulfonyl) imide (Product name: IONEL™), a lithium salt as the advanced electrolyte which was commercialized first in the world by Nippon Shokubai.
1. Background of the alliance
With a rising awareness of environmental issues in recent years, there is a high demand for electric vehicle (EV), which is an industry-leading product of energy-saving and low-pollution next-generation vehicles, and this has led to the rapid expansion of the LIB market for EV. Because using LiFSI as an electrolyte in LIB for EV significantly improves the battery’s cyclic and rate performance as well as storing stability over a wide temperature range from low to high temperatures, LiFSI has been adapted not only as an additive, but also as a main ingredient of the electrolyte. As this has led to a surge in LiFSI demand particularly in Asia and Europe, early business expansion to China, the world’s biggest LIB market for vehicles has been a key for us to make a big leap in our IONEL™ business.
2. Purpose of the alliance
Under these circumstances, in order to acquire high-profile customers and early establish a cost-competitive manufacturing and sales structure in China with the largest LIB demand, we have decided to form an alliance with Capchem, a major electrolyte solution manufacturer, and Toyota Tsusho Corporation (Headquarters: Nagoya, Japan, President: Ichiro Kashitani, hereinafter “Toyota Tsusho”), who is Toyota Group’s general trading company. The investment will be made by Toyota Tsusho (Shanghai) Co., Ltd. (hereinafter “Toyotsu Shanghai”). This will allow us to combine our state-of-the-art LiFSI production technologies, quality control capability, and intellectual properties with Hunan Fluopont’s cost-competitiveness, location, material procurement capability, production system, and existing technologies, and Capchem’s LiFSI purchasing capability supported by their top-level supply capacity of electrolyte solutions, as well as Toyota Tsusho’s world-wide sales network encompassing China. Through this alliance, we will aim to accelerate our IONEL™ business in the electrolyte market.
LiFSI is known as a difficult substance to purify to a high degree, which is only achieved by advanced know-how for its production and quality management. Using our unique production technology that we have nurtured over the years, in 2013, we succeeded in the development of an industrial production process of highly-pure LiFSI with few solvents and by-products, exhibiting stable electrochemical properties, for the first time in the world. Our product has been adopted and certified as the electrolyte by many LIB manufacturers inside and outside Japan with a wide variety of applications including vehicle, consumer-use, and stationary batteries.
(For details of LiFSI, please refer to our website: https://www.shokubai.co.jp/en/lp/ionel/)
Capchem is the world’s second largest manufacturer of electrolyte solution for LIB with five production sites in China, and has a track record of providing its products to major LIB manufacturers. Their business includes not only manufacturing of electrolyte solution, but also in-house material production of solvent, electrolyte, additive, which enables them to offer electrolyte solution with price competitiveness and high quality.
Toyota Tsusho is looking to expand their LiFSI sales beyond China to electrolyte solution manufactures in Japan, Asia, and Europe to meet the surging demand in the electrolyte solution and electrolyte markets.
Hunan Fluopont started its production in the second half of FY2022 with the first unit (production capacity 1,200t/y). It is planned to be expanded in stages to satisfy the rapidly increasing market demand, aiming to have annual production capacity of 12,000 ton/y in 2025.
3. Investment overview
Nippon Shokubai and Toyotsu Shanghai will invest in the following company. |
||
(1) |
Company name |
|
|
Hunan Fluopont New Materials Co., Ltd. |
|
(2) |
Location |
|
|
Shigu District, Hengyang, Hunan, China |
|
(3) |
Amount invested (third-party allocation of shares) |
|
|
Nippon Shokubai: 201,769,912 RMB (4.04 billion JPY) |
|
|
Toyotsu Shanghai: 29,203,539 renminbi (580 million JPY) |
|
|
[Assumed exchange rate: 20 JPY/RMB] |
|
(4) |
Shareholders |
|
|
Capchem: 51.19% |
|
|
Nippon Shokubai: 38.0% |
|
|
Toyotsu Shanghai: 5.5% |
|
|
Changsha ShinLian Huayuan Alternative Energy Partnership Enterprise (shareholding association by executive employees of Hunan Fluopont): 5.31% |
|
(5) |
Representative |
|
|
Shu Ping Ai |
|
(6) |
Businesses |
|
|
Manufacturing and sales of electrolyte LiFSI for LIB |
|
(7) |
Production capacity |
|
|
Current: 1,200t/year in the second half of FY2022 |
|
|
Plan: 12,000t/year in FY2025 |
|
Related information
Profile of Shenzhen CAPCHEM Technology Co. Ltd. |
|
Company Name |
Shenzhen CAPCHEM Technology Co. Ltd. |
Location |
Capchem Plaza, Changye Road, Pingshan District, Shenzhen, Guangdong Province, China. |
Establishment |
1996 |
Capital |
410 million RMB (8.2 billion JPY) (as of end of 2021) |
Total assets |
223.3 billion JPY (as of end of 2021) |
Sales |
139 billion JPY (FY2021) |
Operating profit |
30.8 billion JPY (FY2021) |
Business overview |
Lithium battery chemicals, organic fluorine chemicals, capacitor chemicals and semiconductor chemicals. For lithium-ion battery electrolytes in mass production at five production sites in China and several other production sites under construction in China and Poland. |
Website |
|
Profile of Toyota Tsusho Corporation |
|
Company Name |
Toyota Tsusho Corporation |
Location |
9-8, Meieki 4-chome, Nakamura-ku, Nagoya 450-8575 Japan |
Establishment |
1948 |
Capital |
64.9 billion yen (as of end of March 2022) |
Total assets |
6,143.1 billion yen (as of end of March 2022) |
Sales |
8,028 billion yen (FY 2021) |
Operating profit |
294.1 billion yen (FY 2021) |
Business overview |
As a general trading company of Toyota Group, the company has expanded its business with a focus on exports of vehicles and automobile production support. The company has seven business fields (Metals, Global Parts & Logistics, Automotive, Machinery, Energy & Project , Chemicals & Electronics, , Food & Consumer Services, and Africa). and focuses on three core businesses, Mobility business that contributes to future convenient society, Resources & Environment business that contributes to sustainable society and Life & Community business that contributes to comfortable & healthy society. Around 65,000 Group employees are engaged in business in about 130 countries. |
Website |
|
Profile of Toyotsu Shanghai |
|
Company Name |
TOYOTA TSUSHO (SHANGHAI) CO.,LTD. |
Location |
1717 Nanjing West Road, Jinganqu, Shanghai, China |
Establishment |
1995 |
Capital |
33.18 million RMB (660 million JPY) (as of end of March 2022) |
Business overview |
The company mainly operates trading businesses with a wide variety of business units including Metal, Global and Logistics, Chemical Products and Electronics, Mechanical and Energy Plant Project, Food and Household Items, and East Asia Next Mobility Promotion Project. |
About NIPPON SHOKUBAI: Since 1941, Nippon Shokubai has grown up its business with unique catalyst technology. Nippon Shokubai has supplied, for example, ethylene oxide and acrylic acid. Among all, our production capacity of superabsorbent polymers is the largest in the world (according to Nippon Shokubai research). We are currently focused on the Solutions Business, and IONEL (LiFSI) mentioned on this announcement plays a key role in accelerating the business. Nippon Shokubai is a global chemical company operating under its corporate mission “TechnoAmenity - Providing prosperity and comfort to people and society, with our unique technology.”
https://www.shokubai.co.jp/en/
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220908006154/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
The Opening of Jayasom Wellness Resort Advancing AMAALA’s Wellness Vision16.9.2026 14:23:00 CEST | Press release
The latest addition to AMAALA’s wellness ecosystem integrates evidence-based practices with Arab and Eastern healing practices complemented by personalized wellness programs Red Sea Global (RSG), the regenerative tourism developer, has opened Jayasom Wellness Resort AMAALA, bringing a distinctive holistic health offering to the destination. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260916231950/en/ Outdoor relaxation area at Jayasom Wellness Resort AMAALA, where serene design and sea-facing spaces create a setting for rest and renewal. Designed by Heah & Co., with interiors by Studio Carter, Jayasom Wellness Resort AMAALA is located on Triple Bay’s largest cove and comprises 153 keys alongside 24 residences. The resort forms part of AMAALA’s secluded wellness core on the Red Sea coast, where nature and hospitality come together in a setting designed for reflection and renewal. “As we launch the first Jayasom globally, w
Rubedo Life Sciences Announces Clinical Study to Treat Hair Loss with GPX4 Modulator RLS-1496, First Human Ex Vivo Evidence Demonstrates Robust Hair Follicle Growth16.9.2026 14:01:00 CEST | Press release
AGA clinical trial to begin in Fall 2026 led by David Pariser, MD, FACP, FAAD, former President of the American Academy of Dermatology and Principal Investigator in more than 450 dermatology clinical trialsRubedo’s RLS-1496, the first and only GPX4 modulator currently in clinical trials, demonstrates superior hair follicle restoration in human ex vivo androgenetic alopecia (AGA) model, matching or outperforming finasteride; findings consistent with dual SenoAdaptive mechanism that activates dormant hair follicle Rubedo Life Sciences, Inc. (Rubedo) today announced a new clinical study of investigational RLS-1496 in patients with androgenetic alopecia (AGA), beginning October 2026, with initial data expected in the first half of 2027. The study marks the first-ever clinical evaluation of a GPX4 modulator in hair loss, extending the program that established RLS-1496 as the world’s first GPX4 modulator to enter human clinical trials of any kind. This press release features multimedia. View
NetApp and Tampa Bay Buccaneers Partner to Enable Data-Driven Operational Excellence16.9.2026 14:00:00 CEST | Press release
New sponsorship expands NetApp’s presence across the NFL, delivering trusted data, intelligence, and the ability to perform in critical moments NetApp® (NASDAQ: NTAP), the Intelligent Data Infrastructure company, today announced that they have been named an Official Partner of the Tampa Bay Buccaneers. This new relationship builds on NetApp’s status as the Official Intelligent Data Infrastructure Partner of the NFL, helping the league and its teams quickly and confidently access, manage, and activate their data. The Buccaneers will leverage NetApp technology to support the experience for Buccaneers fans in the stadium on game days and beyond. “NetApp will serve as a trusted technology partner that will help us elevate the customer experience for all Buccaneers fans,” said Buccaneers Chief Commercial Officer Atul Khosla. “Reliable and secure access to data plays an essential role in the overall game day experience at Raymond James Stadium. NetApp’s industry-leading intelligent data infr
Unique Australian Clay: Multi Minerals Australia’s Non-antibiotic Solution for Poultry Production16.9.2026 13:44:00 CEST | Press release
Multi Minerals Australia, a leading mining company, announced a one-of-a-kind formulation of Australian clays which has proven it can reshape the global poultry feed economic landscape. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260916711777/en/ Unique, non-antibiotic clay stockfeed component and production enhancer from Multi Minerals Australia. Sourced from its one-of-a-kind geological deposit. Proven results. Worldwide distribution. Potential applications and lower cost benefits to a range of commercial animal production, particularly poultry. Expressions of interest sought. Numerous scientific, clinical, and commercial producer validations have demonstrated the product’s significant benefits; including the reduction of feed costs; improvements in: growth; meat yield; feed conversion; resistance to heat stress; eggshell quality and production: reduced inflammation and mortality in layer and broiler production. It has
Compass Pathways to Participate in TD Cowen 6th Annual Novel Mechanisms in Neuropsychiatry Summit on September 23, 202616.9.2026 12:30:00 CEST | Press release
Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to unlocking urgently needed new treatment options in mental health care, announced today that management will attend the TD Cowen 6th Annual Novel Mechanisms in Neuropsychiatry Summit on September 23, 2026 and will participate in a fireside chat at 1:00pm ET. A live audio webcast of the fireside chat will be accessible at the following link: https://event.summitcast.com/view/fAK4ioHxQNLX5A2utMmqiy/2vkuNBQpn65oayAPDgU4rZ A replay of the webcast will be accessible for 30 days following each event at the “Events” page of the Investors section of the Compass website. About Compass Pathways We believe mental health patients deserve the possibility of a better future. Compass Pathways plc (Nasdaq: CMPS) is a biotechnology company dedicated to unlocking urgently needed new treatment options in mental health care. Our initial focus is developing COMP360 psilocybin, a proprietary, investigational, synthetic psilocybin treat
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
